PROGRESSIVE'S EVENING STROLL DATE: 25 November, 2026

Market Snapshot:

After a strong gap-up start, the Index extended its gains, supported by BFSI stocks, before giving back some of them mid-session. Support from FMCG and Pharma stocks helped it recover, and the Index closed at 25,819.25, up 469.60 points. FMCG led sectoral gains, rising 3.79%, followed by Pharma and BankNifty, while Metals continued to underperform, falling 2.04%. The rally remained concentrated in Index stocks only; Midcap gained just 0.30%, while Smallcap ended in the red, both lagging Nifty50.

HOW THE DAY TRENDED



INDICES

Index	Close	Points	%Chg.
Sensex	83938.28	1502.29	**1.82**
Nifty50	25819.25	469.60	**1.85**
Nifty Midcap 100	61584.75	181.55	**0.30**
Nifty Small Cap 100	19229.35	(85.05)	**(0.44)**

SECTORAL GAINERS / LOSERS

Sectors	Close	Points	%Chg.
NIFTY FMCG	50143.50	1830.95	**3.79**
NIFTY PHARMA	28961.90	673.05	**2.38**
NIFTY BANK	63703.25	1117.90	**1.79**
NIFTY METAL	11578.50	(240.75)	**(2.04)**

NIFTY TOP GAINERS / LOSERS

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
HUL	2141.80	**6.08**	TATA STEEL	159.30	**(2.27)**
TATA CONSUMER	1185.80	**4.66**	MAX HEALTHCARE	1076.30	**(1.22)**
HDFC LIFE	601.30	**4.58**	HINDALCO	889.90	**(1.17)**
NESTLE IND	1358.50	**4.03**	JSW STEEL	1302.50	**(0.72)**

INDICES LEVELS FOR November 26, 2026

Nifty (future)	
Resistance	26230
Support	25790

Bank Nifty (future)	
Resistance	64900
Support	63200



PROGRESSIVE'S EVENING STROLL DATE: 25 November, 2026

KEY TAKEAWAYS OF THE DAY

- **ABB to acquire EC Fan maker Ziehl-Abegg for USD2.65bn:**

ABB announced an agreement to acquire Ziehl-Abegg, a German manufacturer of electronically commutated (EC) fans and integrated electric motors, for an enterprise value of USD2.65bn. The deal adds EC fans to ABB's Motion portfolio of motors and drives. It broadens ABB's offering for HVAC, industrial cooling and thermal management applications.

- **Gland Pharma's Visakhapatnam facility clears USFDA's inspection:**

The company's VSEZ Sterile Oncology Formulations Facility and API Facility at Visakhapatnam has cleared an inspection from the USFDA. Following the routine GMP inspection at the company's VSEZ Sterile Oncology Formulations Facility and API Facility at Visakhapatnam between August 24, 2026 and September 01, 2026; the company has received an Establishment Inspection Report (EIR) from the USFDA.

- **Brigade Group records Rs1,600cr sales in launch weekend at Brigade Autograph:**

The launch of Floris, the first residential phase of Brigade Autograph, received an overwhelming response from customers, with Brigade recording sales worth Rs1,600cr over the launch weekend. Brigade Autograph has a GDV of approx. Rs12,000cr and comprises around 8 million square feet of commercial and residential saleable area. The development will be launched in multiple phases over the next few quarters.

- **RMC Switchgears receives Rs521.84cr Maharashtra EPC LOI:**

The company has received a LoI for the development of distribution infrastructure and system-strengthening works. The project covers the construction of new substations, augmentation of existing substations, installation of additional power transformers, HT lines and allied works. The estimated basic order cost stands at Rs521.84cr.

- **GSK India launches antibody-drug conjugate BLENREP for multiple myeloma:**

GSK India announced the launch of a drug in India as a combination therapy for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The new drug, BLENREP (belantamab mafodotin), has been approved by the Central Drugs Standard Control Organisation (CDSCO). BLENREP is the world's first approved antibody-drug conjugate targeting B-cell maturation antigen (BCMA) for multiple myeloma and marks GSK's third precision oncology therapy in the country. Following the launch of Jemperli and Zejula in solid tumours, the introduction of BLENREP marks the company's expansion into haemato-oncology.

Source: Media Reports



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai—400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Mamatha Poojari,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500.

Grievance Officer:
Email: grievancecell@progressiveshares.com

